KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
122 hedge funds and large institutions have $561M invested in KalVista Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 50 increasing their positions, 32 reducing their positions, and 13 closing their positions.
327% more call options, than puts
Call options by funds: $5.82M | Put options by funds: $1.36M
56% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 32
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
3% more funds holding
Funds holding: 119 → 122 (+3)
1% less capital invested
Capital invested by funds: $568M → $561M (-$7.25M)
2.31% less ownership
Funds ownership: 114.33% → 112.01% (-2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$21.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.48M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$5.76M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$2.52M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$2.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTM
First Turn Management
Del Mar,
California
|
-$8.86M |
| 2 |
SC
Stempoint Capital
New York
|
-$8.68M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.93M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$7.19M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$6.31M |
KALV Hedge Fund Activity: Q3 2024 in Review
122 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2024, worth a combined $561M — down 1.3% from $568M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KALV positions and 13 closed out — a net gain of 4 holders — while 50 added to existing stakes and 32 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $21.4M. The largest seller was First Turn Management, cutting an estimated $8.86M.
- 122 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2024, up from 119 in Q2 2024.
- Funds reported $561M of KalVista Pharmaceuticals stock for Q3 2024, down 1.3% quarter-over-quarter.
- 17 funds opened new KalVista Pharmaceuticals positions in Q3 2024 and 13 closed out, a net change of +4 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2024 was Vestal Point Capital, an estimated $21.4M added.
- The largest KalVista Pharmaceuticals seller in Q3 2024 was First Turn Management, an estimated $8.86M sold.
Based on aggregated 13F filings for Q3 2024.